Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + TKI vs Active Surveillance in Adjuvant HCC
NCT06059885Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Dec 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Tumor Recurrence Rate (DRR) at 52 weeks and Safety and Adverse Events. Started Dec 2021; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06059885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059885.